A recent study reveals that people who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who stop conventional lifestyle programs.
Research printed in a leading medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals using these medications need to be informed of the danger of quick rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
That rate of recovery means a reversion to starting mass within about one and a half years.
Comparing Treatments
The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that people who shed pounds through diet and exercise usually see a slower creep back—approximately 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Experts believe the mechanism of the injections is key to understanding the amplified rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in hunger is unsuppressed, making binge eating far more likely."
A Chronic Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of relapse, the therapy might need to be life-long.
This perspective is supported by drug manufacturers, who state that the results "highlight the long-term character of obesity," comparing it to managing conditions like high blood pressure.
User Accounts
Individuals who have stopped the medication report a sudden resurgence of hunger.
"I experienced a trigger that goes on and you become ravenous," said a patient.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit changes during treatment.
Growing Adoption
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and maintained weight loss hinges on ongoing behavioural changes.
